Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone

Biological Psychiatry

Volumn 68, Issue 3, 2010, Pages 296-302

  Hulse, Gary K ^a   Ngo, Hanh T T ^a   Tait, Robert J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Heroin craving; heroin dependence; implant naltrexone; naltrexone level; oral naltrexone; relapse; risk factor

Indexed keywords

NALTREXONE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; FOLLOW UP; HEROIN DEPENDENCE; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK FACTOR; SINGLE DRUG DOSE; WITHDRAWAL SYNDROME;

ADULT; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG IMPLANTS; DRUG-SEEKING BEHAVIOR; FEMALE; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT COMPLIANCE; RECURRENCE; RISK FACTORS; TABLETS; TREATMENT OUTCOME;

EID: 77955710583     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.04.003     Document Type: Article

References (28)

1. C. Brewer Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: A report of two cases Addict Biol 7 2002 321 323
2. C.N. Chiang, L.E. Hollister, H.K. Gillespie, and R.L. Foltz Clinical evaluation of a naltrexone sustained-release preparation Drug Alcohol Depend 16 1985 1 8
3. V. Navaratnam, A. Jamaludin, N. Raman, M. Mohamed, and S.M. Mansor Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts Drug Alcohol Depend 34 1994 231 236
4. K. Verebey, J. Volavka, S.J. Mule, and R.B. Resnick Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing Clin Pharmacol Ther 20 1976 315 328
5. U. Kirchmayer, M. Davoli, and A. Verster Naltrexone maintenance treatment for opioid dependence Cochrane Database Syst Rev 2 2003 CD001333
6. S.D. Comer, M.A. Sullivan, and G.K. Hulse Sustained-release naltrexone: Novel treatment for opioid dependence Expert Opin Investig Drugs 16 2007 1285 1294
7. S. Comer, M.A. Sullivan, E. Yu, J.L. Rothenberg, H.D. Kleber, and K. Kampman Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial Arch Gen Psychiatry 63 2006 210 218
8. N. Kunoe, P. Lobmaier, J.K. Vederhus, B. Hjerkinn, S. Hegstad, and M. Gossop Naltrexone implants after in-patient treatment for opioid dependence: Randomised controlled trial Br J Psychiatry 194 2009 541 546
9. G.K. Hulse, N. Morris, D. Arnold-Reed, and R.J. Tait Improving clinical outcomes in treating heroin dependence Arch Gen Psychiatry 66 2009 1108 1115
10. G.K. Hulse, D.E. Arnold-Reed, G. O'Neil, C.T. Chan, R. Hansson, and P. O'Neil Blood naltrexone and 6-β-naltrexol levels following naltrexone implant: Comparing two naltrexone implants Addict Biol 9 2004 59 65
11. H.T. Ngo, D.E. Arnold-Reed, R.C. Hansson, R.J. Tait, and G.K. Hulse Blood naltrexone levels over time following naltrexone implants Prog Neuropsychopharmacol Biol Psychiatry 32 2008 23 28
12. G.K. Hulse, and M.R. Basso The association between naltrexone compliance and daily supervision Drug Alcohol Rev 19 2000 41 48
13. S. Darke, J. Ward, W. Hall, N. Heather, and A. Wodak The Opiate Treatment Index (OTI) Researchers' Manual 1991 National Drug and Alcohol Research Centre Sydney, Australia
14. R. Hansson, and E. Toh Free Naltrexone and 6-β-Naltrexol in Whole Blood by LC-MS-MS 2000 Chemistry Centre Perth, Western Australia
15. SAS Institute Inc. SAS 9.1 2nd ed. 20022003 SAS Institute Inc Cary, NC
16. O. Kuss, How to Use SAS for Logistic Regression with Correlated Data 2002 SAS Users Group International, April 1417 Orlando, Florida
17. C.N. Chiang, A. Kishimoto, G. Barnett, E. Leo, and L.E. Hollister Implantable narcotic antagonists: A possible new treatment for narcotic addiction Psychopharmacol Bull 21 1985 672 675
18. G.K. Hulse, R.J. Tait, S.D. Comer, M.A. Sullivan, I.G. Jacobs, and D.E. Arnold-Reed Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants Drug Alcohol Depend 79 2005 351 357
19. B.A.G. Dijkstra, C.A.J. De Jong, S.M. Bluschke, P.F.M. Krabbe, and C.P.F. van der Staak Does naltrexone affect craving in abstinent opioid-dependent patients? Addict Biol 12 2007 176 182
20. S.I. Sideroff, V.C. Charuvastra, M.E. Jarvik, and J. Ouren Craving in heroin addicts maintained on the opiate antagonist naltrexone Am J Drug Alcohol Abuse 5 1978 415 423
21. E.M. Krupitsky, E.E. Zvartau, D.V. Masalov, M.V. Tsoi, A.M. Burakov, and V.Y. Egorova Naltrexone for heroin dependence treatment in St. Petersburg, Russia J Subst Abuse Treat 26 2004 285 294
22. E.M. Krupitsky, E.E. Zvartau, D.V. Masalov, M.V. Tsoy, A.M. Burakov, and V.Y. Egorova Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia J Subst Abuse Treat 31 2006 319 328
23. S. Grsser, C.Platz W., Glz J. Thalemann, and G. Partecke A new approach to preventing relapse in opiate addicts: A psychometric evaluation Biol Psychol 71 2006 231 235
24. M.C. Meyer, A.B. Straughn, M.W. Lo, W.L. Schary, and C.C. Whitney Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration J Clin Psychiatry 45 1984 15 19
25. M.K. Greenwald, and S.R. Hursh Behavioral economic analysis of opioid consumption in heroin-dependent individuals: Effects of unit price and pre-session drug supply Drug Alcohol Depend 85 2006 35 48
26. A.J. Heinz, D.H. Epstein, J.R. Schroeder, E.G. Singleton, S.J. Heishman, and K.L. Preston Heroin and cocaine craving and use during treatment: Measurement validation and potential relationships J Subst Abuse Treat 31 2006 355 364
27. I.H.A. Franken, V.M. Hendriks, and W. Van Den Brink Initial validation of two opiate craving questionnaires: The Obsessive Compulsive Drug Use Scale and the Desires for Drug Questionnaire Addict Behav 27 2002 675 685
28. H.T.T. Ngo, R.J. Tait, and G.K. Hulse Hospital psychiatric comorbidity and its role in heroin dependence treatment outcomes using naltrexone implant or methadone maintenance [published online ahead of print April 1] J Psychopharmacol 2010 doi:10.1177/0269881110364266